(MENAFN- Brazil-Arab News Agency (ANBA))
São Paulo – Egypt intends to be self-sufficient in the production of vaccines against COVID-19. Egyptian pharmaceutical company Pharco wants to start producing the Russian Sputnik V vaccine before the end of the year. Egypt also expects to begin manufacturing the Chinese Sinovac vaccine and is in talks to produce the British AstraZeneca. In addition, research is underway to develop an Egyptian vaccine. The news is from the Egyptian newspaper Al Ahram.
According to a statement from the Egyptian Ministry of Health and Population, three million shots will be manufactured daily in a new complex of the Holding Company for Biological Products and Vaccines (VACSERA), an Egyptian company. The complex was established at a total cost of USD 33 million and is the largest vaccine production plant in the Middle East and North Africa (MENA) region. The site has eight laboratories and the capacity to store 150 million shots at appropriate temperatures.
The Egyptian Ministry of Health stated the VACSERA complex is expected to produce 40 million shots of the Chinese Sinovac vaccine this year and 2 million shots within a month.
About two million people have been vaccinated against COVID-19 in the Arab country since February, and another 3.5 million have registered for vaccination. The number of vaccination centers has increased to 400 nationwide to cater to the increased demand.
The Ministry informed that Egypt initially aims at self-sufficiency in the production of vaccines. Later on, it could start exporting vaccines to Arab and African countries.
Translated by Elúsio Brasileiro
The post Egypt seeks vaccine production self-sufficiency appeared first on Agência de Notícias Brasil-Árabe .
MENAFN24062021000213011057ID1102341513
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.